rs61748436
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000554.6(CRX):c.122G>A(p.Arg41Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000805 in 1,614,018 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R41P) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000554.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CRX | NM_000554.6 | c.122G>A | p.Arg41Gln | missense_variant | 3/4 | ENST00000221996.12 | NP_000545.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CRX | ENST00000221996.12 | c.122G>A | p.Arg41Gln | missense_variant | 3/4 | 2 | NM_000554.6 | ENSP00000221996.5 | ||
CRX | ENST00000556527.1 | n.99G>A | non_coding_transcript_exon_variant | 2/2 | 1 | |||||
CRX | ENST00000566686.5 | c.122G>A | p.Arg41Gln | missense_variant | 3/3 | 5 | ENSP00000457808.2 | |||
CRX | ENST00000613299.1 | c.100+1721G>A | intron_variant | 3 | ENSP00000478106.1 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152134Hom.: 0 Cov.: 32
GnomAD4 exome AF: 0.00000752 AC: 11AN: 1461884Hom.: 0 Cov.: 32 AF XY: 0.00000688 AC XY: 5AN XY: 727242
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152134Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74328
ClinVar
Submissions by phenotype
not provided Pathogenic:2Other:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Oct 23, 2020 | - - |
not provided, no classification provided | literature only | Retina International | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Apr 01, 2017 | - - |
Retinal dystrophy Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Blueprint Genetics | Oct 11, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, Univ. Regensburg, Univ. Regensburg | Jan 01, 2022 | - - |
Cone-rod dystrophy 2 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 01, 1998 | - - |
Leber congenital amaurosis 7;C3489532:Cone-rod dystrophy 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 06, 2023 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 41 of the CRX protein (p.Arg41Gln). This variant is present in population databases (rs61748436, gnomAD 0.007%). This missense change has been observed in individuals with autosomal dominant and autosomal recessive retinal disease (PMID: 9427255, 11748859, 24265693, 29068479, 30543658, 31215831; Invitae). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 7421). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CRX protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects CRX function (PMID: 11971869). For these reasons, this variant has been classified as Pathogenic. - |
CRX-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 17, 2024 | The CRX c.122G>A variant is predicted to result in the amino acid substitution p.Arg41Gln. This variant has been reported in multiple individuals with CRX-related retinal disease (for examples, see Swain et al. 1997. PubMed ID: 9427255; Blanco-Kelly et al. 2012. PubMed ID: 22736939, Eisenberger et al. 2013. PubMed ID: 24265693). This variant is located in the DNA-binding domain of the CRX protein and is predicted to reduce DNA-binding activity (Swain et al. 1997. PubMed ID: 9427255). Variants impacting the same amino acid have been shown to be pathogenic for CRC-related retinal disease (p.Arg41Trp; Swain et al. 1997). PubMed ID: 9427255This variant is reported in 0.0065% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at